Unlock stock picks and a broker-level newsfeed that powers Wall Street.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?

In This Article:

IDEXX Laboratories, Inc. IDXX is slated to report fourth-quarter 2021 results on Feb 2, before market open.

In the last-reported quarter, the company’s earnings per share of $2.03 surpassed the Zacks Consensus Estimate by 7.9%. Moreover, earnings outpaced the consensus estimate in the trailing four quarters, the average beat being 25.40%.

Let’s take a look at how things have shaped up prior to this announcement.

Factors at Play

The Companion Animal Group (CAG) business is expected to have gained from consistent and healthy organic revenue growth in the to-be-reported quarter, backed by strong performance in CAG diagnostics recurring business in the United States and internationally. Robust growth in the U.S. clinical business is likely to have contributed to the U.S. CAG Diagnostic recurring revenue gains. In its earnings call for the third quarter, the company noted that U.S. clinical visit growth rose 2%, with strength across non-wellness and wellness visit categories. The CAG arm is also likely to gain from the organic growth in CAG diagnostic instrument revenues, as it did in the prior quarter.

We expect the company to report significant growth in IDEXX’s global catalyst installed base in the fourth quarter on new instrument placements and high customer retention levels, as experienced in the prior quarter. Notably, total premium placements in the third quarter totaled 4307 units. The company also recorded 344 catalyst placements on continued strong demand from high-volume customers in the prior quarter. Further, the company’s premium hematology placements were up 62% in the last-reported quarter. In the fourth quarter, despite the emergence of the new variants of COVID-19, the overall opening up of the economy is unabated. Further, the global rollout of ProCyte One continues to support strong overall placement momentum with the majority of our ProCyte One placements. Under such a situation, we expect the company to have recognized strong market demand leading to high instrument placements. These developments are likely to have driven the fourth-quarter top line.

The ezyVet acquisition, completed in June, expanded IDEXX’s cloud-based software capability and is expected to have fueled growth in the CAG arm. The company’s veterinary software and diagnostic are also expected to report strong growth for the fourth quarter on gains in PIMS placements and continued strong growth in related recurring service, similar to the prior quarter, with initial benefits from the recent ezyVet buyout.

The Zacks Consensus Estimate for CAG revenues is pegged at $696 million, suggesting an improvement of 10.5% from the year-ago quarter’s reported figure.